Related Experiment Video
Updated: May 15, 2025
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
Assessment of Seizure Action Plans in Pediatric Convulsive Status Epilepticus: Focus on Benzodiazepine-Responsive and
Coral M Stredny1, Sahar Rostamian1, Theodore Alexander Sheehan1
1Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, MA.
Insights
Personalized seizure action plans (SAPs) significantly reduce treatment times and seizure duration in pediatric convulsive status epilepticus (CSE). Implementing SAPs and treatment algorithms improves patient outcomes and lowers intubation rates.
Area of Science:
- Pediatric Neurology
- Emergency Medicine
- Clinical Research
Background:
- Optimal acute treatment is critical for pediatric convulsive status epilepticus (CSE).
- Limited data exist on the impact of seizure action plans (SAPs) and treatment algorithms on CSE outcomes.
- Understanding treatment adherence in benzodiazepine (BZD)-responsive vs. BZD-resistant CSE is essential.
Purpose of the Study:
- To examine treatment algorithm adherence in pediatric CSE.
- To investigate the relationship between personalized SAPs and treatment process/outcomes.
- To compare outcomes in BZD-responsive and BZD-resistant CSE patients.
Main Methods:
- Prospective observational cohort study of pediatric CSE (≥5 minutes duration).
- Evaluation of patient care processes and outcomes.
- Univariate statistical analysis of data from February 2016 to July 2018.
Main Results:
- Patients with personalized SAPs received the first antiseizure medication (ASM) faster (6 vs. 15 minutes).
- Personalized SAP implementation was linked to shorter seizure duration (9 vs. 22 minutes) and lower intubation rates (14% vs. 53%).
- BZD-resistant patients showed lower treatment protocol adherence and slower time to first ASM.
Conclusions:
- Personalized SAPs and treatment algorithm implementation are associated with improved process and outcome measures in pediatric CSE.
- Faster ASM administration and reduced seizure duration observed with SAP use.
- Adherence to treatment protocols is crucial, especially in BZD-resistant cases.
Background And Objectives:
Optimal acute treatment is crucial in pediatric convulsive status epilepticus (CSE). However, data on the benefits of seizure action plans (SAPs) and treatment algorithm implementation in relation to process and outcome measures in CSE are scarce. Our study examines treatment algorithm adherence in benzodiazepine (BZD)-responsive and BZD-resistant groups and specifically focuses on the relationship with personalized SAPs.
Methods:
We performed a prospective observational cohort study evaluating patient care processes and outcomes in young patients with CSE lasting ≥5 minutes, requiring admission and an antiseizure medication(s) (ASM) for seizure termination from February 2016 to July 2018. Patients with infantile spasms, invasive EEG monitoring, unclear seizure duration, unclear ASM administration time, or seizure cluster were excluded. We used univariate statistics to analyze the data.
Results:
We enrolled 60 patients (median age 3.7 [1.9-7.0] years, 48% female), including 34 BZD-responsive and 26 BZD-resistant patients. Patients who had access to a personalized SAP, even if it was not adhered to, experienced a median (p25-p75) time to first ASM of 6 minutes (5-18; n = 34). By contrast, patients without access to a personalized SAP had a longer median (p25-p75) time to the first ASM of 15 minutes (8-27; n = 24; p < 0.05). The median (p25-p75) time to administer the first ASM was 6 (5-15; n = 33) minutes in BZD-responsive patients vs 15 (6-32; n = 25; p < 0.05) minutes in BZD-resistant patients. Treatment protocol implementation rates were lower in BZD-resistant vs BZD-responsive patients. The median (p25-p75) time to administer the first ASM was 5 minutes (4-5; n = 14) in patients who implemented a personalized SAP compared with 16 minutes (6-31; n = 20; p < 0.001) in patients without SAP implementation. The median (p25-p75) seizure duration in personalized SAP implementation and nonimplementation groups was 9 (6-16; n = 14) and 22 (11-64; n = 20; p < 0.01) minutes, respectively. The intubation rate was 14% for those who implemented the personalized SAP and 53% for those who did not (p < 0.05).
Discussion:
Seizure duration was shorter in patients with personalized SAP, and the time to administer ASM was faster. In addition, BZD-resistant patients were less likely to follow treatment protocols, and the time to first-line therapy was slower. SAP and algorithm implementation was associated with a lower intubation rate, indicating potential benefits, including improved process and patient outcome measures.
More Related Videos
Related Concept Videos
01:13Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:24Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...